Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Miglustat Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C9646-A

    Miglustat Coverage for Type 1 Gaucher Disease and Niemann-Pick Disease Type C

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C9646-A alerts

    Get alerted when Policy C9646-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for oral miglustat products in adults with mild-to-moderate Type 1 Gaucher disease when enzyme replacement therapy is not a therapeutic option, and in members with Niemann-Pick disease type C with qualifying neurologic, psychiatric, or cognitive manifestations.

    Policy Summary
    PayerMolina Healthcare
    PolicyMiglustat Coverage for Type 1 Gaucher Disease and Niemann-Pick Disease Type C
    Policy CodePolicy C9646-A
    Change TypeAnnual reviewno material change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization requests with a covered indication, required clinical documentation, applicable criteria, quantity limits, and qualified specialist prescribing or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered disease indications
    18+Minimum member age
    12 moAuthorization duration
    300 mg/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Gaucher disease quantity limit
    600 mg/dayNiemann-Pick disease quantity limit

    Covered Uses and Limitations

    Initial Therapy: Type 1 Gaucher Disease

    Covered when all of the following Type 1 Gaucher disease criteria are met.

    Type 1 Gaucher disease initial therapy

    • Diagnostic confirmation: Diagnosis is confirmed by glucocerebrosidase activity in white blood cells or skin fibroblasts ≤30% of normal activity, or by genotype testing showing mutations in both glucocerebrosidase alleles.≤30% of normal activity

      Documentation required.

    • Symptomatic disease: At least one qualifying manifestation is documented: anemia, hepatomegaly, splenomegaly, skeletal disease, abdominal or bone pain, fatigue, exertional limitation, weakness, cachexia, or thrombocytopenia.At least 1 manifestation
    • Enzyme replacement therapy is not a therapeutic option: Rationale is documented for not using imiglucerase, velaglucerase, or taliglucerase, such as refractory or intolerant disease, allergy or hypersensitivity, or poor venous access.
    • Therapeutic goals: Member-specific therapeutic goals are documented based on baseline symptoms, overall health, and quality of life.

      Examples include bone pain, fatigue, dyspnea, angina, or abdominal discomfort.

    Initial Therapy: Niemann-Pick Disease Type C

    Covered when all of the following Niemann-Pick disease type C criteria are met.

    Niemann-Pick disease type C initial therapy

    • Diagnosis: Documented diagnosis of Niemann-Pick disease type C.
    • Genetic confirmation: Genetic testing identifies both disease-causing alleles in NPC1 or NPC2.Both disease-causing alleles

      Documentation required.

    • Clinical manifestations: Mild-to-moderate neurologic, psychiatric, or cognitive manifestations are documented.Mild-to-moderate

    Continuation Therapy

    Continuation authorization requires the applicable disease-specific criteria.

    Continuation therapy

    • Type 1 Gaucher disease continuation: Improvement in or stabilization from baseline is documented based on therapeutic goals, and no intolerable adverse effects or drug toxicity are present.

      Response may include spleen volume, hemoglobin, liver volume, platelet count sufficient to decrease bleeding risk, growth, bone pain, or bone crisis.

    • Niemann-Pick disease type C continuation: The prescriber attests or clinical reviewer finds no evidence of intolerable adverse effects or drug toxicity.

    All other uses of Zavesca or other miglustat products are considered experimental or investigational and are handled under Molina’s Off-Label policy. Examples include GM2 gangliosidoses, such as Tay-Sachs and Sandhoff disease, mucopolysaccharidosis type III, and Type 3 Gaucher disease.

    Miglustat should not be used for Niemann-Pick disease type C when no neurologic manifestations are present. Coverage is supported for members with mild-to-moderate neurologic, psychiatric, or cognitive manifestations; the best attainable outcome may be neurologic stabilization or a slower rate of disease progression.

    Coding and Clinical Thresholds

    High Risk Alertmixed
    No codes listed
    Hemoglobin Threshold
    Hemoglobin thresholdLess than 9 g/dL
    Applies toSevere Type 1 Gaucher disease
    Coverage implicationSafety and efficacy of miglustat have not been established in individuals meeting this severe-disease threshold.
    Platelet Count Threshold
    Platelet count thresholdLess than 50,000/mm3
    Equivalent measureLess than 50 × 10^9/L
    Applies toSevere Type 1 Gaucher disease

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for miglustat requests under this policy. Coverage is limited to qualifying adult members with a covered indication, and the request must satisfy the applicable clinical criteria, documentation requirements, prescriber requirements, and quantity limits.

    • Covered indications: mild-to-moderate Type 1 Gaucher disease when enzyme replacement therapy is not a therapeutic option, or Niemann-Pick disease type C with qualifying manifestations.
    • Member must be 18 years of age or older.
    • Submit consultation notes with initial authorization and reauthorization requests when the prescriber is treating in consultation with a qualified specialist.
    Documentation Required

    Required Clinical Documentation

    Submit complete clinical documentation to support medical necessity and the requested indication. Molina may request additional records and may deny reimbursement when documentation does not establish medical necessity, a noninvestigational use, or benefit eligibility.

    Disease and Treatment Context

    Type 1 Gaucher disease is a non-neuronopathic autosomal recessive lysosomal storage disorder caused by deficient glucocerebrosidase activity, which leads to accumulation of glucosylceramide. Common clinical features include hepatosplenomegaly, anemia, thrombocytopenia, and skeletal disease. Miglustat is an oral substrate-reduction therapy that decreases glycosphingolipid glucosylceramide formation and may be considered for adults with mild-to-moderate disease when enzyme replacement therapy is not a therapeutic option.

    Policy Definitions

    Severe Type 1 Gaucher Disease
    HemoglobinLess than 9 g/dL
    Platelet countLess than 50,000/mm3 (less than 50 × 10^9/L)
    Active bone diseaseAlso qualifies as severe Type 1 Gaucher disease, regardless of the listed blood-count thresholds.
    Gaucher Disease
    Disease typeRare autosomal recessive lysosomal storage disorder
    Underlying causeMutations in the glucocerebrosidase gene
    Disease mechanismGlucosylceramide accumulates in macrophage cells.

    Initial Therapy Requirements

    Initial Therapy: Type 1 Gaucher Disease

    Type 1 Gaucher disease initial therapy requires all listed clinical, diagnostic, symptom, treatment-rationale, and therapeutic-goal criteria.

    Type 1 Gaucher disease

    • Diagnostic confirmation: Diagnosis is confirmed by glucocerebrosidase activity in white blood cells or skin fibroblasts ≤30% of normal activity, or by genotype testing showing mutations in both glucocerebrosidase alleles.≤30% of normal activity

      Documentation required.

    • Qualifying symptomatic manifestation: At least one qualifying manifestation is documented: anemia, hepatomegaly, splenomegaly, skeletal disease, abdominal or bone pain, fatigue, exertional limitation, weakness, cachexia, or thrombocytopenia.At least 1 manifestation

    Continuation Authorization

    Continuation Therapy

    Continuation authorization requires disease-specific response or safety criteria.

    Continuation therapy

    • Type 1 Gaucher disease: Improvement or stabilization is documented from baseline based on therapeutic goals, with no intolerable adverse effects or drug toxicity.

      Relevant goals may include spleen volume, hemoglobin, liver volume, platelet count, growth, bone pain, or bone crisis.

    • Niemann-Pick disease type C: The prescriber attests or clinical reviewer finds no evidence of intolerable adverse effects or drug toxicity.

    Dose and Quantity Limits

    Miglustat Quantity Limit
    Quantity limit300 mg per day
    Capsule equivalent3 capsules per day
    Covered indicationMild-to-moderate Type 1 Gaucher disease
    Miglustat Quantity Limit
    Quantity limit600 mg per day
    Capsule equivalent6 capsules per day
    Covered indicationNiemann-Pick disease type C

    Administration and Pharmacy Benefit

    Note

    Use pharmacy benefit coverage for home self-administration

    Oral medication is recommended for pharmacy benefit coverage and patient self-administration. Miglustat is administered by the oral route.

    Policy Summary
    PayerMolina Healthcare
    PolicyMiglustat Coverage for Type 1 Gaucher Disease and Niemann-Pick Disease Type C
    Policy CodePolicy C9646-A
    Change TypeAnnual reviewno material change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization requests with a covered indication, required clinical documentation, applicable criteria, quantity limits, and qualified specialist prescribing or consultation.
    SourceLink
    On This Page
    Covered Uses and LimitationsCoding and Clinical ThresholdsAuthorization, Documentation, and Denial RisksDisease and Treatment ContextPolicy DefinitionsInitial Therapy RequirementsContinuation AuthorizationDose and Quantity LimitsAdministration and Pharmacy Benefit
    Glucocerebrosidase Activity
    Glucocerebrosidase activity thresholdLess than or equal to 30% of normal activity
    Testing specimensWhite blood cells or skin fibroblasts
    Use in coverage reviewQualifying enzyme activity can confirm the Type 1 Gaucher disease diagnosis.
    • Confirm the diagnosis with the required laboratory or genetic testing.
    • Document qualifying signs, symptoms, or neurologic, psychiatric, or cognitive manifestations, as applicable.
    • Provide the clinical rationale for treatment, including why enzyme replacement therapy is not a therapeutic option for Type 1 Gaucher disease.
    • Include therapeutic goals, baseline status, relevant test results, patient records, and specialist consultation notes when applicable.
    Documentation Required

    Submit Member-Specific Dosing Information

    When the requested product is dosed using a member-specific measurement, include that measurement with the medical-necessity request so Molina can evaluate the dose.

    • Submit the relevant member-specific dosing data, such as weight, body surface area, or another measurement used for dosing.
    Billing Rule

    Use Industry-Standard Coding

    Providers and facilities must use industry-standard coding practices for all submissions. Code listings or billing under this policy do not guarantee coverage; payment remains subject to the member’s benefit document and applicable policy requirements.

    • Use current, accurate CPT, HCPCS, ICD-10, and other applicable industry-standard codes.
    • Deleted, invalid, or ineffective codes may not be eligible for reimbursement.
    Denial Risk

    Denial Risk: Severe Type 1 Gaucher Disease

    Requests for severe Type 1 Gaucher disease are at risk for denial because miglustat safety and efficacy have not been established for this severity level.

    • Severe disease includes hemoglobin concentration < 9 g/dL.
    • Severe disease includes platelet count < 50,000/mm³ (< 50 × 10⁹/L).
    • Active bone disease also meets the policy’s severe-disease definition.
    Denial Risk

    Denial Risk: Unconfirmed or Nonqualifying Diagnosis

    A request may be denied when the diagnosis is not confirmed or the member does not meet the policy’s qualifying clinical criteria. Do not submit Type 1 Gaucher disease requests without the required confirmatory testing and symptomatic manifestations.

    • Type 1 Gaucher disease requires glucocerebrosidase activity ≤ 30% of normal in white blood cells or skin fibroblasts, or genotype testing showing mutations in both alleles of the glucocerebrosidase gene.
    • Type 1 Gaucher disease also requires at least one qualifying manifestation, such as anemia, hepatosplenomegaly, skeletal disease, abdominal or bone pain, fatigue, exertional limitation, weakness, cachexia, or thrombocytopenia.
    • Niemann-Pick disease type C requires the diagnosis and the qualifying manifestations described in the separate Niemann-Pick criteria.
    Denial Risk

    Denial Risk: Enzyme Replacement Therapy Remains an Option

    For Type 1 Gaucher disease, document why enzyme replacement therapy is not a therapeutic option before requesting miglustat. A request may be denied when enzyme replacement remains clinically appropriate and no qualifying exception is documented.

    • Acceptable rationale may include refractory disease or intolerance, allergy or hypersensitivity to enzyme replacement therapy, or poor venous access.
    • Relevant enzyme replacement products include imiglucerase (Cerezyme), velaglucerase (Vpriv), and taliglucerase (Elelyso).
    Denial Risk

    Denial Risk: Nonqualifying Niemann-Pick Disease Type C

    Niemann-Pick disease type C requests may be denied when genetic confirmation or qualifying manifestations are absent. Coverage requires both disease-causing allele confirmation and mild-to-moderate neurologic, psychiatric, or cognitive manifestations.

    • Genetic testing must identify both disease-causing alleles in NPC1 or NPC2.
    • Do not submit requests based solely on cholestatic or systemic symptoms or for members without neurologic manifestations.
    • Explain that the expected treatment goal is neurologic stabilization or slower progression; effectiveness for Niemann-Pick disease type C is unproven.
    Denial Risk

    Uncovered or Investigational Uses

    Uses of miglustat outside the covered Type 1 Gaucher disease and Niemann-Pick disease type C criteria are considered experimental or investigational and are not covered under this policy. Such requests follow Molina’s Off-Label policy.

    • Investigational or unsupported uses include other miglustat indications such as GM2 gangliosidoses, mucopolysaccharidosis type III, and Type 3 Gaucher disease.
    • Submit any exception or off-label request under the applicable Molina Off-Label policy and include complete medical rationale.
    Denial Risk

    Denial Risk: Age Restriction

    The member must be at least 18 years old to meet this policy requirement. Requests for members younger than 18 years do not qualify for coverage under these criteria.

    • Age requirement: 18 years of age and older.
    Billing Rule

    Improper Billing or Noncovered Benefit

    Molina may reject or deny claims and recover payments when billing is inappropriate, the service is not a covered benefit, or submitted documentation does not support the determination.

    • Verify benefit eligibility and coverage before dispensing or billing.
    • Use accurate, current coding and retain records supporting medical necessity.
    • Payment is not guaranteed merely because a code appears in the policy.
    Commonly involved areasLiver, spleen, bone marrow, blood, and bones
    Niemann-Pick Disease Type C
    Disease typeRare genetic lysosomal storage disorder
    Underlying causeMutations in the NPC1 or NPC2 genes
    Cellular effectImpaired cellular processing and transport of low-density lipoprotein (LDL) cholesterol
    Accumulating substancesUnesterified cholesterol and glycosphingolipids
    Treatment rationale: Rationale is documented for why enzyme replacement therapy is not a therapeutic option, including imiglucerase, velaglucerase, or taliglucerase; examples include refractory or intolerant disease, allergy or hypersensitivity, or poor venous access.
  1. Therapeutic goals: Member-specific therapeutic goals are documented based on baseline symptoms, overall health, and quality of life.

    Examples include bone pain, fatigue, dyspnea, angina, or abdominal discomfort.

  2. Initial Therapy: Niemann-Pick Disease Type C

    Niemann-Pick disease type C initial therapy requires all listed diagnostic and qualifying manifestation criteria.

    Niemann-Pick disease type C

    • Diagnosis: Documented diagnosis of Niemann-Pick disease type C.
    • Genetic confirmation: Genetic testing identifies both disease-causing alleles in NPC1 or NPC2.Both disease-causing alleles

      Documentation required.

    • Qualifying manifestations: Mild-to-moderate neurologic, psychiatric, or cognitive manifestations are documented.Mild-to-moderate